Related Experiment Videos
MR imaging assessment of experimental hepatic dysfunction with Mn-DPDP
B D Coley1, R F Mattrey, K G Baker
1Department of Radiology, University of California, San Diego Medical Center 92103, USA.
Journal of Magnetic Resonance Imaging : JMRI
|January 1, 1995
Summary
Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate) (Mn-DPDP) magnetic resonance contrast agent shows distinct liver and gallbladder enhancement patterns. These patterns help differentiate normal livers from those with severe or subtle impairment.
Area of Science:
- Radiology
- Hepatology
- Pharmacology
Background:
- Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate) (Mn-DPDP) is a paramagnetic MR contrast agent.
- It enhances liver visibility and is primarily excreted via the biliary system.
Purpose of the Study:
- To evaluate the utility of Mn-DPDP in diagnosing diffuse liver disease.
- To assess liver and gallbladder enhancement patterns in a rabbit model.
Main Methods:
- 24 rabbits underwent induced conditions: total biliary occlusion, segmental biliary occlusion, or galactosamine-induced hepatitis.
- MR imaging was performed at baseline and for 1 hour post-intravenous Mn-DPDP administration.
- Temporal hepatic and gallbladder enhancement patterns were analyzed.
Main Results:
- Baseline MR imaging did not distinguish between normal and abnormal livers, except in segmental occlusion.
- Hepatic enhancement patterns differed significantly between groups, with total occlusion showing markedly lower signal intensity.
- Gallbladder enhancement patterns showed greater differentiation among the groups.
Conclusions:
- Mn-DPDP's temporal hepatic enhancement patterns can identify severely impaired livers.
- Gallbladder enhancement patterns aid in distinguishing subtly impaired livers, enhancing diagnostic utility for diffuse liver disease.